BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 31819405)

  • 21. Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.
    Calverley PM; Eriksson G; Jenkins CR; Anzueto AR; Make BJ; Persson A; Fagerås M; Postma DS
    Int J Chron Obstruct Pulmon Dis; 2017; 12():13-25. PubMed ID: 28031707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
    Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD.
    Criner GJ; Connett JE; Aaron SD; Albert RK; Bailey WC; Casaburi R; Cooper JA; Curtis JL; Dransfield MT; Han MK; Make B; Marchetti N; Martinez FJ; Niewoehner DE; Scanlon PD; Sciurba FC; Scharf SM; Sin DD; Voelker H; Washko GR; Woodruff PG; Lazarus SC; ;
    N Engl J Med; 2014 Jun; 370(23):2201-10. PubMed ID: 24836125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A score to predict short-term risk of COPD exacerbations (SCOPEX).
    Make BJ; Eriksson G; Calverley PM; Jenkins CR; Postma DS; Peterson S; Östlund O; Anzueto A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():201-9. PubMed ID: 25670896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
    Beeh KM; Beier J; Candler H; Wittig T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2877-2884. PubMed ID: 27920515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
    Wedzicha JA; Buhl R; Lawrence D; Young D
    Respir Med; 2015 Jan; 109(1):105-11. PubMed ID: 25433954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD.
    Dal Negro RW; Visconti M; Micheletto C; Tognella S
    Pulm Pharmacol Ther; 2008; 21(2):304-8. PubMed ID: 17889580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erdosteine reduces the exercise-induced oxidative stress in patients with severe COPD: Results of a placebo-controlled trial.
    Dal Negro RW; Visconti M
    Pulm Pharmacol Ther; 2016 Dec; 41():48-51. PubMed ID: 27651323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial.
    Watz H; Tetzlaff K; Magnussen H; Mueller A; Rodriguez-Roisin R; Wouters EFM; Vogelmeier C; Calverley PMA
    Respir Res; 2018 Dec; 19(1):251. PubMed ID: 30545350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erdosteine in children and adults with bronchiectasis (BETTER trial): study protocol for a multicentre, double-blind, randomised controlled trial.
    Chang AB; Yerkovich ST; Baines KJ; Burr L; Champion A; Chatfield MD; Eg KP; Goyal V; Marsh RL; McCallum GB; McElrea M; McPhail S; Morgan LC; Morris PS; Nathan AM; O'Farrell H; Sanchez MO; Parsons M; Schultz A; Torzillo PJ; West NP; Versteegh L; Marchant JM; Grimwood K
    BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38719503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial.
    van Velzen P; Ter Riet G; Bresser P; Baars JJ; van den Berg BTJ; van den Berg JWK; Brinkman P; Dagelet JWF; Daniels JMA; Groeneveld-Tjiong DRGL; Jonkers RE; van Kan C; Krouwels FH; Pool K; Rudolphus A; Sterk PJ; Prins JM
    Lancet Respir Med; 2017 Jun; 5(6):492-499. PubMed ID: 28483402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [ Erdosteine (Mucodox), oral administration].
    J Pharm Belg; 2011 Jun; (2):55-6. PubMed ID: 21823444
    [No Abstract]   [Full Text] [Related]  

  • 35. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
    Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of mild exacerbation on COPD symptoms in a Japanese cohort.
    Sato M; Chubachi S; Sasaki M; Haraguchi M; Kameyama N; Tsutsumi A; Takahashi S; Nakamura H; Asano K; Betsuyaku T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1269-78. PubMed ID: 27354785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    JAMA; 2018 Oct; 320(15):1548-1559. PubMed ID: 30326124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erdosteine affects eicosanoid production in COPD.
    Dal Negro RW; Visconti M; Tognella S; Micheletto C
    Int J Clin Pharmacol Ther; 2011 Jan; 49(1):41-5. PubMed ID: 21176724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study.
    Zheng JP; Kang J; Huang SG; Chen P; Yao WZ; Yang L; Bai CX; Wang CZ; Wang C; Chen BY; Shi Y; Liu CT; Chen P; Li Q; Wang ZS; Huang YJ; Luo ZY; Chen FP; Yuan JZ; Yuan BT; Qian HP; Zhi RC; Zhong NS
    Lancet; 2008 Jun; 371(9629):2013-8. PubMed ID: 18555912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations.
    Jones PW; Willits LR; Burge PS; Calverley PM;
    Eur Respir J; 2003 Jan; 21(1):68-73. PubMed ID: 12570111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.